Get the Stockscreener App
83.70
1.34%
-1.14
Pre-market:
83.60
-0.10
-0.12%
Incyte Corp stock is traded at $83.70, with a volume of 1.01M.
It is down -1.34% in the last 24 hours and up +19.30% over the past month.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
See More
Previous Close:
$84.84
Open:
$84.26
24h Volume:
1.01M
Relative Volume:
0.55
Market Cap:
$16.34B
Revenue:
$4.58B
Net Income/Loss:
$870.87M
P/E Ratio:
19.02
EPS:
4.4
Net Cash Flow:
$945.58M
1W Performance:
-3.27%
1M Performance:
+19.30%
6M Performance:
+14.38%
1Y Performance:
+27.51%
1-Day Range:
$83.50
$84.58
1-Week Range:
$83.50
$87.00
52-Week Range:
$53.56
$87.24
Incyte Corp Stock (INCY) Company Profile
Name
Incyte Corp
Sector
Industry
Phone
(302) 498-6700
Address
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
83.70 | 16.57B | 4.58B | 870.87M | 945.58M | 4.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.05 | 99.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
579.61 | 62.21B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.33 | 59.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
704.07 | 43.33B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
297.96 | 35.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-01-25 | Initiated | Barclays | Overweight |
| Jun-16-25 | Upgrade | Stifel | Hold → Buy |
| Mar-18-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-18-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-17-24 | Initiated | UBS | Neutral |
| Oct-29-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-01-24 | Initiated | Wolfe Research | Outperform |
| Sep-18-24 | Downgrade | Truist | Buy → Hold |
| Jul-02-24 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| May-23-24 | Initiated | Deutsche Bank | Hold |
| Apr-23-24 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-23-24 | Initiated | Jefferies | Buy |
| Feb-14-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-13-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-21-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-25-23 | Initiated | Citigroup | Buy |
| May-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-10-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-24-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Jan-31-23 | Initiated | Piper Sandler | Overweight |
| Aug-03-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-28-22 | Initiated | Wells Fargo | Equal Weight |
| Feb-09-22 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-18-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Jul-20-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-10-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-07-21 | Initiated | Truist | Buy |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-16-20 | Initiated | The Benchmark Company | Hold |
| May-06-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-29-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-24-20 | Resumed | William Blair | Outperform |
| Mar-13-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-04-20 | Resumed | BofA/Merrill | Neutral |
| Jan-03-20 | Reiterated | BMO Capital Markets | Market Perform |
| Jan-03-20 | Downgrade | Mizuho | Buy → Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-03-19 | Initiated | Mizuho | Buy |
| Sep-12-19 | Initiated | BMO Capital Markets | Market Perform |
| Sep-05-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-05-19 | Upgrade | Oppenheimer | Perform → Outperform |
| May-21-19 | Initiated | Credit Suisse | Neutral |
| May-03-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-19 | Initiated | Stifel | Hold |
| Apr-03-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-24-19 | Upgrade | William Blair | Mkt Perform → Outperform |
View All
Incyte Corp Stock (INCY) Latest News
Long term hold vs stop loss in Incyte CorporationDividend Hike & Weekly High Return Stock Forecasts - Newser
Should you wait for a breakout in Incyte CorporationQuarterly Growth Report & AI Driven Stock Reports - Newser
What candlestick patterns are forming on Incyte CorporationTrade Risk Report & Free Long-Term Investment Growth Plans - Newser
Applying Elliott Wave Theory to Incyte CorporationJuly 2025 News Drivers & Real-Time Buy Signal Alerts - Newser
Detecting support and resistance levels for Incyte CorporationJuly 2025 Selloffs & Technical Confirmation Trade Alerts - Newser
Quantitative breakdown of Incyte Corporation recent move2025 Major Catalysts & Reliable Entry Point Trade Alerts - Newser
How sentiment analysis helps forecast Incyte Corporation2025 Price Momentum & Short-Term Swing Trade Alerts - Newser
Are Wall Street Analysts Predicting Incyte Stock Will Climb or Sink? - MSN
What indicators show strength in Incyte CorporationPortfolio Risk Summary & Fast Moving Trade Plans - Newser
Published on: 2025-08-28 10:23:57 - Newser
Evaluating Incyte Corporation with trendline analysis2025 Institutional Moves & Weekly Market Pulse Updates - Newser
Will breakout in Incyte Corporation lead to full recoveryDollar Strength & Capital Efficiency Focused Ideas - Newser
What’s the recovery path for long term holders of Incyte CorporationJuly 2025 Decliners & Breakout Confirmation Alerts - Newser
Incyte Corporation (INCY) Expands Precision Medicine with QIAGEN Partnership - Insider Monkey
Can technical indicators confirm Incyte Corporation’s reversalJuly 2025 Trends & Target Return Focused Stock Picks - Newser
Reversal indicators forming on Incyte Corporation stock2025 Trading Volume Trends & Stock Timing and Entry Methods - Newser
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)August 27, 2025 - BioSpace
Chart based analysis of Incyte Corporation trends2025 Stock Rankings & Growth Oriented Trading Recommendations - Newser
Incyte reports inducement grant under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Using RSI to spot recovery in Incyte CorporationMarket Trend Summary & Growth Focused Entry Reports - Newser
Will Incyte Corporation stock recover after recent dropQuarterly Investment Review & Safe Entry Momentum Tips - Newser
What institutional flow reveals about Incyte CorporationBull Run & Safe Capital Growth Plans - Newser
What Fibonacci levels say about Incyte Corporation reboundLayoff News & Safe Entry Zone Tips - Newser
Three Biotech Companies to Watch: Boston Scientific, Arcutis Biotherapeutics, and Incyte Corporation - AInvest
How institutional ownership impacts Incyte Corporation stockJuly 2025 Highlights & Safe Swing Trade Setup Alerts - Newser
Will Incyte Corporation rebound enough to break evenJuly 2025 Spike Watch & Weekly Setup with High ROI Potential - Newser
How to escape a deep drawdown in Incyte Corporation2025 Growth vs Value & Weekly Market Pulse Updates - Newser
Incyte appoints Soni Basi as new chief human resources officer - Investing.com
Incyte Announces Executive Changes, Effective August 25, 2025 - MarketScreener
Incyte Corporation Company’s Quarterly Earnings Growth: What the Numbers SayQuarterly Profit Summary & Risk Controlled Daily Plans - Newser
Analyzing Incyte Corporation with risk reward ratio charts2025 Investor Takeaways & Real-Time Chart Breakout Alerts - Newser
How Incyte Corporation stock performs during market volatility2025 Major Catalysts & AI Optimized Trade Strategies - beatles.ru
Market Wrap: Is Incyte Corporation impacted by rising rates2025 Market Sentiment & Weekly High Momentum Picks - theviewers.co.kr
Apache, Incyte, Prudential, ON Semiconductor: 'Mad Money' Lightning Round - TheStreet
Incyte Corp. Stock Down Despite Market Surge - AInvest
JP Morgan Maintains Incyte (INCY) Rating, Raises Price Target to $73 | INCY Stock News - GuruFocus
Eli Lilly (LLY) Shares Lower After Update on Rheumatoid Arthritis Drug - TheStreet
JPMorgan Adjusts Price Target on Incyte to $73 From $67, Maintains Neutral Rating - MarketScreener
Incyte describes new MRGPRX2 antagonists - BioWorld MedTech
INCY Stock Trading Close to Its 52-Week High: Buy, Sell or Hold? - Yahoo Finance
Are Wall Street Analysts Predicting Incyte Stock Will Climb Or Sink? - Barchart.com
Incyte Corp Stock (INCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.33%
1.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):